These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

961 related articles for article (PubMed ID: 25810327)

  • 41. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.
    Eriksson M; Käyhty H; Saha H; Lahdenkari M; Koskinen P; Mäkisalo H; Anttila VJ
    Transpl Infect Dis; 2020 Aug; 22(4):e13343. PubMed ID: 32473046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
    Li G; Ren T; Zhang H; Ti J; Chang X; Yin S; Guan Y; Liu G; Liang Q; Liu J
    Vaccine; 2024 Oct; 42(24):126209. PubMed ID: 39217777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
    Kim DS; Shin SH; Lee HJ; Hong YJ; Lee SY; Choi KM; Oh CE; Kim KH; Juergens C; Patterson S; Giardina PC; Gruber WC; Emini EA; Scott DA
    Pediatr Infect Dis J; 2013 Mar; 32(3):266-73. PubMed ID: 23011012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R; Hurley D; Grayson S; Li J; Nolan K; McFetridge RD; Hartzel J; Abeygunawardana C; Winters M; Pujar H; Benner P; Musey L
    Hum Vaccin Immunother; 2019; 15(3):549-559. PubMed ID: 30689507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
    Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
    AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil.
    Rezende RPV; Oliveira-Santos M; Andrade LEC; Klumb EM
    Lupus; 2023 Apr; 32(5):694-703. PubMed ID: 36705619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
    Azuma M; Oishi K; Akeda Y; Morino S; Motoki Y; Hanibuchi M; Nishioka Y
    Vaccine; 2023 Jan; 41(5):1042-1049. PubMed ID: 36593171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
    Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
    Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
    Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
    Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
    Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
    Chichili GR; Smulders R; Santos V; Cywin B; Kovanda L; Van Sant C; Malinoski F; Sebastian S; Siber G; Malley R
    Vaccine; 2022 Jul; 40(31):4190-4198. PubMed ID: 35690500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
    Chu K; Hu Y; Pan H; Wu J; Zhu D; Young MM; Luo L; Yi Z; Giardina PC; Gruber WC; Scott DA; Watson W
    Hum Vaccin Immunother; 2023 Aug; 19(2):2235926. PubMed ID: 37549923
    [No Abstract]   [Full Text] [Related]  

  • 55. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
    Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
    Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional immune responses to 11 non-PCV13 serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Lee S; Kim HW; Lee JH; Kim KH
    Vaccine; 2017 Sep; 35(37):4960-4965. PubMed ID: 28778614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
    Rodgers GL; Esposito S; Principi N; Gutierrez-Brito M; Diez-Domingo J; Pollard AJ; Snape MD; Martinón-Torres F; Gruber WC; Patterson S; Thompson A; Gurtman A; Paradiso P; Scott DA
    Vaccine; 2013 Oct; 31(42):4765-74. PubMed ID: 23965217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
    Korbal P; Wysocki J; Jackowska T; Kline M; Tamimi N; Drozd J; Lei L; Peng Y; Giardina PC; Gruber W; Scott D; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):587-595. PubMed ID: 38456705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
    O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
    Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.